Revenue: 415.8 billion won; net income: 47.3 billion won

Daewoong Pharmaceutical announced on November 4 that its operating profit on a standalone basis for the third quarter of this year rose 43.5% year on year to 76.8 billion won.

An artist's rendering of Daewoong Pharmaceutical's Magok Research Institute in Gangseo-gu, Seoul. Daewoong Pharmaceutical

An artist's rendering of Daewoong Pharmaceutical's Magok Research Institute in Gangseo-gu, Seoul. Daewoong Pharmaceutical

View original image

Revenue for the same period increased 17.1% to 415.8 billion won, while net income rose 9.9% to 47.3 billion won.



A Daewoong Pharmaceutical official said, "The results reflect expanded exports of Nabota, a botulinum toxin product, along with growth in key businesses such as over-the-counter (OTC) medicines and digital healthcare. The increased sales share of high-margin products, led by Nabota, also contributed positively to improving overall profitability."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing